Tyra Biosciences is a clinical-stage biotechnology company headquartered in South San Francisco, California, that focuses on the discovery and development of precision oncology therapies. Founded in 2019, the company leverages a structure-based drug design platform to identify and optimize small-molecule inhibitors that target cancer-driving proteins. Tyra Biosciences has built a pipeline of novel compounds designed to address genetically defined patient populations with high unmet medical need.
The company’s core activities span target discovery, medicinal chemistry, and preclinical development. Utilizing computational modeling and biophysical screening techniques, Tyra Biosciences aims to create molecules with high selectivity and favorable pharmacokinetic properties. Its preclinical portfolio includes candidates designed to inhibit mutant kinases and modulate protein homeostasis pathways, with the goal of advancing lead compounds into Investigational New Drug (IND) applications.
Tyra Biosciences serves a global oncology community through strategic collaborations with academic research institutions and contract research organizations. The company’s research programs benefit from partnerships that provide access to translational biology expertise, patient-derived models, and biomarkers to guide clinical strategy. Although primarily based in the United States, Tyra Biosciences maintains engagement with international investigators to support multi-regional studies.
Under the leadership of Chief Executive Officer Dr. Elan Holman and a management team with extensive experience in cancer drug development, Tyra Biosciences is committed to advancing targeted therapies from the laboratory to the clinic. The company’s scientific advisory board comprises seasoned oncology researchers who contribute to program prioritization and clinical design, positioning Tyra Biosciences to address critical gaps in precision medicine.
AI Generated. May Contain Errors.
